Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?

• DOI: 10.1016/j.gore.2021.100700
• Publication Date: 2021-01-14T16:53:45Z
• Authors: Varun Khetan; Erin A. Blake; Marcia A. Ciccone; Koji Matsuo
• Keywords: 0301 basic medicine; Toxicity; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Case Report; Gynecology and obstetrics; Rhabdomyolysis; 3. Good health; 03 medical and health sciences; Synchronous endometrial and vaginal cancer; Levonorgestrel intrauterine device; RG1-991; Pembrolizumab; RC254-282

• Immune checkpoint inhibitors are approved for all mismatch repair deficient tumors. Although rare, autoimmune myositis complicating pembrolizumab therapy may be fatal. In this case, caused rhabdomyolysis but also a durable response. Severe reaction associated with treatment